Navigation Links
The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol
Date:11/6/2012

LDL receptors in the liver. Without PCSK9 bound to them, the LDL receptors can take up and remove LDL-C from the blood, recycle and remain available for binding additional LDL-C. The Amgen Phase 2 program for AMG 145 enrolled more than 2,000 patients across seven studies to evaluate the effects of AMG 145 across multiple patient populations who may benefit from additional cholesterol lowering treatment options. The Phase 2 program is evaluating the treatment of hyperlipidemia with AMG 145 in combination with statins, in patients with hyperlipidemia who cannot tolerate statins, as a stand-alone treatment in patients with hyperlipidemia, and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous and homozygous familial hypercholesterolemia.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
2. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
3. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
4. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
5. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
6. Publication of PrEP Trial Data Provides Clear Evidence that PrEP Works for Men and Women
7. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
8. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
9. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
10. International Spine Products Manufacturer Featured in Upcoming US Business Executive Publication - www.gsmedicalusa.com
11. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Corporation (Nasdaq: IRIX ) today reported financial results ... , Revenues were $11.8 million in the fourth ... 11% from $10.6 million in the 2013 fourth quarter. Revenues ... from $38.3 million in 2013. , Gross margin for ... the fourth quarter of the prior year. , Operating ...
(Date:3/5/2015)... March 5, 2015  BioPhotas, Inc., an FDA registered ... patented photo-therapeutic technologies to treat skin, muscle and joint ... Semper Fi Fund to provide BioPhotas, flagship product, the ... pain management solutions.  Commenting on the ... who used the Celluma at the Warrior Hope and ...
(Date:3/5/2015)... 5, 2015   ndd Medical Technologies , a ... employs precise ultrasound technology, announced that its EasyOne Pro® ... the San Antonio Pulmonary Fibrosis Support Group. The clinic ... fibrosis (PF), as well as those suspected of having ... a mere 12 square inches, EasyOne Pro provides accurate ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... filtration devices to address infectious disease and cancer, ... entitled: " A Platform to Address Bioterrorism." ... at: http://www.aethlonmedical.com/knowledge-center/special-reports/ ...
... 2010 Northwestern Memorial Hospital is one ... will test whether operable lung cancer patients and their ... by hardwiring data systems to reduce medical error and ... trial co-sponsored by the Commission on Cancer and the ...
Cached Medicine Technology:'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 2'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 3'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 4Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3
(Date:3/6/2015)... CHICAGO (PRWEB) March 06, 2015 As ... and healthcare services programs, the organization has hired two ... Hagerty, Ph.D. They will report to Grace Pavlath, ... Vice President and Scientific Program Director, and together will ... lead to treatments and cures for various types of ...
(Date:3/6/2015)... Parents need to start the discourse with their children ... programs like DARE, or Drug Abuse Resistance Education proved ... Prevention and Education has already impacted a collective 600,000 ... Feb. 27th. As teens continue to suffer fatal overdoses ... are lobbying Florida to pass The Overdose Prevention Act- ...
(Date:3/6/2015)... 06, 2015 At Natural Products ... today the launch of its powerful, location-aware iOS ... and sustainable products at any retailer that carries ... at Expo West Booth 6054. , Makeena’s ... Kosher, non-GMO, organic, Paleo, and vegan, among many ...
(Date:3/6/2015)... 06, 2015 Since Medicare began paying ... there has been an overwhelming demand from providers for ... compliant CCM program. The Centers for Medicare & ... , PYA’s updated white paper—“ Providing and Billing ... into a detailed, yet practical “how to” manual for ...
(Date:3/6/2015)... Jvion, the Atlanta-based leader in clinical ... Difficile (C Diff) predictive use case for inpatient ... is the latest in a broad compliment of ... conditions, and individual illnesses. Using the firm’s RevEgis ... at risk individuals to help support clinician decision-making ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... Nov. 28 Neurobiological,Technologies, Inc (NTI (TM)) (Nasdaq: ... was appointed Chief Medical Officer, effective as of,November ... February 2007 as Vice President, Clinical,Programs with primary ... NTI,s drug candidate for acute ischemic stroke that ...
... Nov. 28 Novant Health(R) today announced ... leader,in developing and manufacturing medical devices for ... implement the Cardiocom System in its,Presbyterian Heart ... Hospital is one of the largest healthcare ...
... Nov. 28 Amedisys, Inc.,(Nasdaq: "AMED" or the "Company"), ... that Larry R. Graham, President and,Chief Operating Officer, and ... 2007 BMO Capital Markets Focus on Healthcare Conference in,New ... will begin at 2:30 p.m. Eastern time. The audio,presentation ...
... WEIFANG, China, Nov. 27 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC ... manufacturer and distributor of high-quality,pharmaceutical grade glucose products in ... presenting at the Roth Capital Phoenix,Conference on November 29, ... Company,s presentation at the,conference are as follows:, ...
... should focus on "dementia red flags" rather than ... they,ve reached a certain age, according to Malaz Boustani, ... and the Regenstrief Institute, Inc. and colleagues from the ... the United Kingdom in a commentary published in the ...
... Nov. 27 S*BIO Pte Ltd today announced ... development,candidate, SB1317. This is a novel orally-available small ... SB1317 is designed to selectively inhibit major ... progression in acute,leukemias. Flt3 mutations are the most ...
Cached Medicine News:Health News:Novant Health(R) Selects Cardiocom(R) to Provide Telemonitoring for Presbyterian Hospital Heart Failure Program 2Health News:Amedisys to Present at 2007 BMO Capital Markets Focus on Healthcare Conference in New York 2Health News:Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference 2Health News:Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference 3Health News:Dementia screening in primary care: Is it time? 2Health News:S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias 2
The Ahmed Glaucoma Valve has been successfully demonstrated to work in all types of glaucoma cases, particularly neovascular, congenital and uvietic glaucoma....
Ahmed Glaucoma Valve Flexible Plate ....
... a robust and durable drainage system. Preplaced ... globe. Pressure Ridge Molteno Implants have a ... tissue, acts as a Pressure sensitive biological ... implants allows the surgeon to choose the ...
... Baerveldt Glaucoma Implants feature a low implant ... reduced complications. The single-quadrant insertion is technically ... seton plate to be installed with less ... fenestrations of the Baerveldt implant were designed ...
Medicine Products: